Emerging as a promising therapeutic approach, Retatrutide is attracting significant buzz within the healthcare community. This novel dual agonist targeting multiple GIP and GLP-1 pathways demonstrates significant results in initial research and ongoing phase 2 human testing. Initial reports suggest considerable body composition and advancements in